3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
3
Phase 2/3
2
Phase 1/2
1
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Interventions
Cisplatin
22
pembrolizumab
17
Drug Therapy
16
Carboplatin
15
Paclitaxel
12
Dexamethasone
12
Gemcitabine
11
Magnetic Resonance Spectroscopy
10
Bevacizumab
10
Docetaxel
9
venetoclax
8
atezolizumab
8
Pemetrexed
8
Oxaliplatin
8
Specimen Handling
7
Radiotherapy
7
Nivolumab
7
Cyclophosphamide
7
Capecitabine
7
Methotrexate
6
130-nm albumin-bound paclitaxel
6
durvalumab
5
blinatumomab
5
Cytarabine
5
Androgen Antagonists
5
tislelizumab
4
spartalizumab
4
pertuzumab
4
Vincristine
4
Trimethoprim, Sulfamethoxazole Drug Combination
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2/3
×
Recruiting
×
budigalimab
×
Clear all
NCT06236438
2026-02-23
LIVIGNO-4
AbbVie
Phase 2/3
Recruiting
840 enrolled
NCT06109272
2025-08-15
LIVIGNO-2
AbbVie
Phase 2/3
Recruiting
660 enrolled